News
TEM
85.01
+3.37%
2.77
Tempus AI, Inc. Class A Ignites Investor Hype
TipRanks · 11h ago
Abeona, NexGen, Nano Nuclear, SanDisk, Tempus Trending
TipRanks · 16h ago
Tempus AI (TEM) Faces A Valuation Test As It Expands Into Whole Genome Sequencing
Simply Wall St · 1d ago
tempus AI Inc Class A call volume above normal and directionally bullish
TipRanks · 2d ago
Tempus AI Chief Accounting Officer Sells $529,650 of Stock
The Motley Fool · 2d ago
Buy 3 AI-Powered Medical Stocks to Strengthen Your Portfolio in Q4
NASDAQ · 2d ago
TempraMed expands LATAM distribution deal and announces C$1M financing
Seeking Alpha · 2d ago
Tempus AI: High Risk, But With A Great Cause
Seeking Alpha · 4d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tempus AI, Inc. Class A (TEM) and Avantor (AVTR)
TipRanks · 4d ago
Tempus AI: Data And Applications Will Unlock More Upside
Seeking Alpha · 4d ago
Moderately bullish activity in tempus AI Inc Class A with shares up 0.51%
TipRanks · 5d ago
Tempus AI: Market Is Hyping On An Uncertain Number
Seeking Alpha · 5d ago
Tempus AI, Recursion extend data license agreement, enter new license agreement
TipRanks · 5d ago
Tempus AI Extends Recursion Data Deal Through 2029, Replacing Potential $84M Fees With $42M In Committed Payments, In Addition To Licensing Recursion’s RNA Foundation Model "TxFM" Under A Separate License Agreement
Benzinga · 5d ago
This Digital Realty Trust Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Benzinga · 5d ago
Cathie Wood's weekly recap: buys $25M of CoreWeave, trims $40M in Bitcoin ETF
Seeking Alpha · 5d ago
Should Whole Genome Platform Require Action From Tempus AI (TEM) Investors?
Simply Wall St · 5d ago
Cathie Wood Sells Tech Favorites Palantir and AMD; Buys Archer Aviation Stock for ARK Innovation ETF
TipRanks · 5d ago
Tempus AI Price Target Announced at $75.00/Share by Goldman Sachs
Dow Jones · 5d ago
Weekly Report: what happened at TEM last week (0914-0918)?
Weekly Report · 5d ago
More
Webull provides a variety of real-time TEM stock news. You can receive the latest news about Tempus AI through multiple platforms. This information may help you make smarter investment decisions.
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.